A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
The purpose of this study is to study the effects, good and bad, of the study drug tazemetostat in combination with doxorubicin on participants and their epithelioid cancer.
soft tissue sarcoma, epithelioid tumors
Must be 18 years or older. Tests and procedures including blood tests, scanning, and a routine physical will be done before you can start to study to see if you are eligible.
18 - 100
Healthy Volunteers Needed
Duration of Participation
For the phase 1b portion, subjects may continue to receive study treatment until disease progression, unacceptable toxicity or withdrawal of consent, or termination of the study.
For the phase 3 portion, subjects will remain on treatment for an average of 10 months.
Knight Cancer Institute Clinical Trials